ROS1-rearranged Non-small Cell Lung Cancer
| Autor: | Lyudmila Bazhenova, Nicholas P. Giustini |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Lung Neoplasms medicine.medical_treatment non-small cell lung cancer (NSCLC) Malignancy Targeted therapy 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins ROS1 Medicine Humans Lung cancer Protein Kinase Inhibitors business.industry Kinase Protein-Tyrosine Kinases medicine.disease respiratory tract diseases 030228 respiratory system Drug Resistance Neoplasm Pharmacogenetics 030220 oncology & carcinogenesis Mutation Cancer research Surgery Signal transduction business Tyrosine kinase |
| Zdroj: | Thoracic surgery clinics. 30(2) |
| ISSN: | 1558-5069 |
| Popis: | ROS1-rearranged non-small cell lung cancer (NSCLC) makes up approximately 1% to 2% of all NSCLC, is oncogenically driven by a constitutively activated ROS1 kinase paired with certain fusion partners, and can be detected by several different assays. These patients are initially treated with tyrosine kinase inhibitors (TKIs), which target the activated ROS1 kinase. Eventually these tumors develop resistance to initial TKI treatment through secondary kinase mutations that block TKI binding or activation of bypass signaling pathways, which subvert ROS1 as the driver of the malignancy. Investigation of several TKIs that have shown efficacy in secondary resistant patients is underway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|